THE US FDA has approved Endari (L-glutamine oral powder) for patients aged five years and older with sickle cell disease, to reduce serious complications associated with the disorder.
Endari has received orphan drug designation for the indication.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Jul 17